Relmada Therapeutics (RLMD) Stock Price & Analysis

RLMD$4.21+0.05 +1.20%
BiotechnologyGrowth Stock
Compare
Market cap$449.19MEnterprise value$432.41MRevenue (TTM)$0Market position—

Score

68
Bullish
Value
57
Quality
47
Growth
100

AI Analysis

Snapshot

Relmada Therapeutics is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 68/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~185% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

57
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

47
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Relmada Therapeutics, Inc. (RLMD) last printed $4.21. Equity value is $449.19M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00

About

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Relmada Therapeutics (RLMD) Stock Price & Analysis

RLMD price $4.21 +0.05 +1.20%

Ticker
RLMD
Price
$4.21
Change
+0.05 +1.20%
Market cap
$449.19M
Dividend yield
0.00%
Beta
0.45
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
68
Value
57
Quality
47
Growth
100

Stocklytics score rationale: value 57, quality 47, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener